Striatum and Hippocampus on Different Time Scales (e-Time)

Assistance Publique - Hôpitaux de Paris

Status: Enrolling

Conditions: Alzheimer Disease; Huntington Disease

Treatments: Other: Temporal perception tasks

Study type: Interventional

Funder types: Other

Identifiers

NCT05943054

APHP20211105

2021-A01008-33 (Other Identifier)

Details and patient eligibility

About

Time processing is fundamental to survival and goal reaching in humans. Different time scales (seconds, minutes, and beyond) are processed through specific cognitive processes involving different neural representations. It is generally agreed that time scale in seconds-to-minutes range named "interval timing" would be anatomically linked to the striatum. Indeed, it is possible to demonstrate a deficit of interval timing processes in patients suffering from striatal damage (Huntington's disease). However, recent findings show involvement of a second brain structure, the hippocampus, in interval timing processing in the minutes range, suggesting an interaction between the striatum and hippocampus. Presumably, patients with hippocampal damage (Alzheimer's disease) would specifically show a decrease in performance for this minutes-range time scale. This study aims to provide a better understanding of the role of the striatum in the treatment of time and its interactions with other brain structures such as the hippocampus. More specifically, it is unclear whether the striatum plays a platform role that would always be involved regardless of the time scale, as suggested by the unified model of time or whether different brain structures is solicited according to the time scale, as suggested by the modular system model. In order to elucidate these issues, a potential double dissociation between brain structures and time scales will be tested.

Full description

In that aim, we will evaluate patients with Huntington's disease and patients with Alzheimer's disease by developing and using time processing paradigms comparing short and long time scales.

Enrollment: 104 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Huntington's disease gene carriers

  • Patient included in the BioHD protocol

  • Age from 18 to 90 years old

  • Symptomatic patient

  • TFC ≥ 11

  • UHDRS motor> 5

  • Native language: French

  • Affiliation to a social security or to another social protection

  • Signature of informed consent

    • Patients with Alzheimer's disease

  • MMS from 20 to 26 (included)

  • Age: from 60 to 90 years old

  • Native language: French

  • Progressive deterioration of memory reported by patient or caregiver for more than 6 months

  • Profile at RL /RI 16: no significant improvement with indexing

  • Episodic memory disorder isolated or associated with other cognitive disorders

  • MRI: Atrophy of the median temporal lobe

  • Affiliation to a social security or to another social protection

  • Signature of informed consent

    • Healthy subjects

  • Healthy subject included in the BioHD protocol

  • MMS ≥ 26

  • Age from 18 to 90 years old

  • Native language: French

  • Affiliation to a social security or to another social protection

  • Signature of informed consent

Exclusion criteria

• Huntington's disease gene carriers

  • Intellectual deterioration preventing understanding of the protocol
  • Other dementia than Huntington's disease
  • Patient living alone at home
  • Major depression
  • Patient under legal protection
  • Patient deprived of liberty
  • Pregnant or breastfeeding woman, situation known to the investigator
  • Inability to handle an electronic tablet

• Patients with Alzheimer's disease

  • Intellectual deterioration preventing understanding of the protocol
  • Patient living alone at home
  • Sudden onset of memory impairment
  • Early onset of the following symptoms: difficulty in walking, convulsions, changes in behavior
  • Focal neurological characteristics including hemiparesis, sensory loss, visual field deficit
  • Early extrapyramidal sign
  • Other dementia than Alzheimer's disease
  • Major depression
  • Cerebrovascular disease
  • Toxic, metabolic or infectious anomaly
  • Patient under legal protection
  • Patient deprived of liberty
  • Pregnant or breastfeeding woman, situation known to the investigator
  • Inability to handle an electronic tablet

• Healthy subjects

  • Intellectual deterioration preventing understanding of the protocol
  • Known neurological or psychiatric illness
  • Patient under legal protection
  • Subject deprived of liberty
  • Pregnant or breastfeeding woman, situation known to the investigator
  • Inability to handle an electronic tablet

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

104 participants in 3 patient groups

Patients carrying the Huntington's gene

Experimental group

Description:

A "long" temporal perception task and a "short" temporal perception task

Treatment:

Other: Temporal perception tasks

Alzheimer's disease patients

Experimental group

Description:

A "long" temporal perception task and a "short" temporal perception task

Treatment:

Other: Temporal perception tasks

Healthy Volunteers

Active Comparator group

Description:

A "long" temporal perception task and a "short" temporal perception task

Treatment:

Other: Temporal perception tasks